Kymera Therapeutics' first-in-class, oral STAT6 degrader, KT-621, has shown positive topline results in an early trial treating patients with moderate to severe atopic dermatitis (AD).
In the Broaden phase 1b clinical trial, KT-621 was tested at 100 mg and 200 mg doses in healthy volunteers and patients with AD. It demonstrated a median reduction of 94% in skin and 98% in blood. It also resulted in a median reduction of 74% in thymus and activation-regulated chemokine (TARC) levels along with other reductions in relevant Type 2 biomarkers in blood, inflammation, and disease-relevant gene sets in skin lesions. In addition, there was a median reduction of 56% in fractional exhaled nitric oxide (FeNO) in patients with comorbid asthma.
Importanty, the drug demonstrated efficacy on par with Sanofi and Regeneron's blockbuster drug, Dupixent, which was first approved for eczema in 2017 and then for AD in March 2019.
The phase 2b Broaden trial in patients with moderate to severe AD is currently ongoing, with data expected for mid-2027. Kymera is also beginning its phase 2b Breadth trial in patients with moderate to severe asthma in the first quarter of 2026.